<a href="https://www.fiercebiotech.com/biotech/abivax-stock-crashes-cancer-cases-overshadow-stellar-efficacy-ulcerative-colitis-phase-3" hreflang="en">Abivax stock suffers as cancer cases overshadow stellar efficacy in ulcerative colitis phase 3 trial</a>
Abivax's stock plummeted by 28% after the company reported cancer cases in patients during a phase 3 trial of its ulcerative colitis drug, obefazimod, despite achieving significant efficacy results with a 40% placebo-adjusted increase in clinical remission rates. The findings raised concerns among investors, overshadowing the drug's potential and efficacy, although some experts downplayed the cancer cases as not alarming.
Abivax's recent phase 3 trial results for obefazimod in ulcerative colitis showcase significant efficacy, with placebo-adjusted clinical remission rates of around 40%. However, the emergence of several cancer cases in the high-dose group has negatively impacted investor confidence, reflected in a 28% drop in share price. For a professional in healthtech and biotech, this underscores the importance of balancing efficacy with safety in drug development and the potential market implications of adverse events, even when efficacy is strong.